Last reviewed · How we verify
NCT07020286
Prince of Wales Hospital Structural Heart Registry
trial testing Structural heart interventions in Structural Heart Abnormality in 1,000 participants. Enrolling by invitation.
30 September 2029
Quick facts
| Lead sponsor | Prince of Wales Hospital, Shatin, Hong Kong |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 1 August 2024 |
| Primary completion | 30 September 2029 |
| Estimated completion | 31 March 2030 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- Structural heart interventions
Conditions studied
- Structural Heart Abnormality — all drugs for Structural Heart Abnormality →
Sponsor
Prince of Wales Hospital, Shatin, Hong Kong
Who can join
Adults 18 to 90, any sex, with Structural Heart Abnormality. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Structural heart disease refers to a group of cardiac defects other than coronary artery disease. Structural heart intervention is a rapidly growing field in cardiology. In the past decade, there has been paradigm shift in the management of structural heart disease from conventional open-heart surgery to transcatheter interventions. With increasing evidence supporting structural heart interventions including transcatheter aortic valve implantation or transcatheter edge to edge repair, there has important updates in recent guidelines in treating structural heart disease. Besides, new device innovations bloomed over the past few years and had expanded the possible treatment options for high surgical risk patients. Some breakthrough devices had been approved recently by the US Food and Drug Administration and some other devices are occasionally used on compassionate ground. However, there has been lack of data in structural heart interventions in Asia Pacific regions outside Japan \[8\]. In this study, we would like to analyze the epidemiological trends, patient characteristics, procedural outcomes and clinical outcomes of structural heart interventions, and compare them with historical cohorts, matched cohort receiving medical therapy and matched cohort receiving open heart surgeries.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07020286
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Structural Heart Abnormality
Currently open trials in the same condition.
- NCT05696522 — Stereotactic Ablative Radiotherapy for the Treatment of Refractory Ventricular Tachycardia · NA · recruiting
Other Prince of Wales Hospital, Shatin, Hong Kong trials
Trials by the same sponsor.
- NCT07455539 — LAmbre™ II Left Atrial Appendage Occluder and Occluder Delivery System for Patients With Non-Valvular Atrial Fibrillatio · NA · not yet recruiting
- NCT07323238 — Hong Kong Cardiogenic Shock Initiative · not yet recruiting
- NCT07516145 — Robotic Transjugular Transcatheter Tricuspid Valve Replacement · NA · recruiting
- NCT07257614 — Left Atrial Appendage Occlusion in Dialysis Patients With Atrial Fibrillation: A Multicentre Pilot Study · not yet recruiting
- NCT07296016 — The Asia-Pacific Mitral & Tricuspid Valve-in-Valve/Valve-in-Ring Registry · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07020286 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Prince of Wales Hospital, Shatin, Hong Kong
- Last refreshed: 13 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07020286.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing